A nationwide recall has been issued for a well-known ADHD medication due to concerns about its effectiveness. Lisdexamfetamine dimesylate capsules, the generic version of Vyvanse, are at the center of this recall, announced on October 28, 2024.
Details of the Recall
The Food and Drug Administration (FDA) reported that several lots of lisdexamfetamine dimesylate capsules failed to meet dissolution tests. This is significant because proper dissolution is crucial for the effective absorption of medications in the human body.
The capsules in question cannot provide an optimal therapeutic effect, which may influence the treatment outcomes for users. However, health officials clarified that taking the recalled medication does not pose any immediate safety risks to patients.
Affected Dosages
The recall encompasses multiple dosage levels of the medication:
- 10 mg
- 20 mg
- 30 mg
- 40 mg
- 50 mg
- 60 mg
- 70 mg
Distribution Timeline
Sun Pharmaceutical Industries, Inc. distributed the impacted lots between May 1, 2024, and November 13, 2024. The medication itself remains valid until 2026.
Next Steps for Patients
Patients who possess the recalled medication are encouraged to consult their doctor or local pharmacy. They can seek guidance on obtaining replacements or refunds for the affected capsules.
